Best Small Cap Stocks To Keep An Eye On – November 28th

by · The Markets Daily

SMX (Security Matters) Public, Spring Valley Acquisition, Bitfarms, Pasithea Therapeutics, and Direxion Daily GOOGL Bull 2X Shares are the five Small Cap stocks to watch today, according to MarketBeat’s stock screener tool. Small-cap stocks are shares of publicly traded companies with relatively small market capitalizations—typically roughly $300 million to $2 billion, though exact cutoffs vary by index provider. They often offer higher growth potential but come with greater volatility, lower liquidity, and higher risk compared with large-cap stocks, making them appealing to investors seeking growth who can tolerate more risk. These companies had the highest dollar trading volume of any Small Cap stocks within the last several days.

SMX (Security Matters) Public (SMX)

SMX (Security Matters) Public Limited Company, through its subsidiaries, engages in the development and commercialization of track and trace technologies for various industries. It owns and commercializes technology to mark various objects, such as solid, liquid, or gas allowing identification, circularity, proof of authenticity, tracking supply chain movements, and quality assurance.

Read Our Latest Research Report on SMX

Spring Valley Acquisition (SV)

Read Our Latest Research Report on SV

Bitfarms (BITF)

Bitfarms Ltd. engages in the mining of cryptocurrency coins and tokens in Canada, the United States, Paraguay, and Argentina. It owns and operates server farms that primarily validates transactions on the Bitcoin Blockchain and earning cryptocurrency from block rewards and transaction fees. The company also provides electrician services to commercial and residential customers in Quebec, Canada.

Read Our Latest Research Report on BITF

Pasithea Therapeutics (KTTA)

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications.

Read Our Latest Research Report on KTTA

Direxion Daily GOOGL Bull 2X Shares (GGLL)

Read Our Latest Research Report on GGLL

Recommended Stories